Cuts To The 340B Drug Pricing Program May Render U.S.Hospitals Serving Vulnerable Patient Groups Vulnerable Themselves

ahfwebUncategorized

CENTENNIAL (S&P Global Ratings) May 25, 2018–S&P Global Ratings today said that it believes the impacts of the cuts to the 340B Drug Pricing Program on not-for-profit hospitals that rely on 340B drug savings will likely weaken their operating performance at a time of already tightening margins. This could lead to negative rating actions if hospital-specific funding reductions were material … Read More

Cuts to the 340B program threaten rural hospitals

ahfwebUncategorized

As leaders in Washington debate ways to lower prescription drug prices, it’s important to remember that many Americans are getting access to free or heavily discounted care through the crucial 340B drug pricing program. This is especially true in rural communities such as here in Boone County in central Iowa, where access to high-quality care is often threatened by economic … Read More

Commentary: Attacks on 340B program distract from source of drug-pricing problem

ahfwebUncategorized

By Dr. Bruce Siegel Given all the good things hospitals accomplish thanks to 340B Drug Pricing Program savings—from affordable medications to comprehensive services for the poor—it might seem odd the program has taken so much heat lately. But if you consider the larger context of the attacks—the national debate on runaway drug prices—you’ll understand why drugmakers have worked so hard … Read More

May 15 Hearing on 340B

ahfwebUncategorized

CONSUMER GROUPS BACK 340B — More than 60 patient groups are urging congressional leaders to support the federal drug discount program that’s been the subject of intensifying congressional scrutiny ahead of another Senate HELP Committee hearing this morning. Families USA, Doctors for America, Public Citizen and others write that they “welcome vigorous oversight” but are urging lawmakers to “reject any proposals that weaken this important … Read More

RWC-340B Responds to Rep. Scott Peters’ Open Letter to Grantees

ahfwebUncategorized

From Ryan White Clinics for 340B Access We write to respond to your February “Open Letter to Grantees” regarding your sponsorship of H.R. 4710, the 340B PAUSE Act.  We strongly agree that the 340B program is “one of Congress’ significant bipartisan achievements” and that it should be “preserved, strengthened, and protected.”  However, we are compelled to address several points made … Read More

Don’t be “Phooled” by PhRMA

ahfwebUncategorized

The 340B Drug Program’s intent is to help safety-net providers “stretch scarce federal resources” to provide more and better services to their clients. The 340B program is saving lives while pharma corporate interests are blaming it for high drug prices. Help save the 340B program from sneak attacks. Save the safety net. Protect and defend the 340B Drug Program. Why … Read More

340B Is Up for Review and Needs Your Help

ahfwebUncategorized

Amid the many issues Congress has on its agenda, 340B is being pushed to the forefront because of the drug industry’s lobbying efforts. The 340B Drug Pricing Program will be up for review in the U.S. Senate’s Health, Education, Labor and Pensions (HELP) Committee hearing on Thursday, March 15. Advocates for 340B have been going to both congressional offices on Capitol … Read More

New Analysis Shows 340B Tax-Exempt Hospitals Provided More Than $50 Billion in Total Benefits to Their Communities

ahfwebUncategorized

By The American Hospital Association WASHINGTON, DC (March 1, 2018) – Hospitals of all kinds provide a full range of benefits to their communities.  In a new analysis released today, the American Hospital Association (AHA) spotlights how 340B tax-exempt hospitals provided more than $50 billion in total benefits to their communities in 2015 alone, the most recent year for which data is available. … Read More

New England Journal of Medicine Presents Distorted View of 340B Program

ahfwebUncategorized

On January 24th, the New England Journal of Medicine (“NEJM”) published a study linking the 340B program to an increase in hospital-physician consolidation in the specialties of hematology-oncology and suggesting that 340B hospitals do not use program savings to benefit indigent patients.  The study focused solely on Disproportionate Share Hospitals (“DSH”) enrolled in the 340B program, but could have implications for other … Read More